
Investigational RNAi Therapeutic Patisiran Meets Primary and All Secondary Endpoints, with Highly Significant Reduction In Neuropathy Progression and Improvement in Quality of Life at 18 Months Relative to Placebo Alnylam Intends to File New Drug Application (NDA) in Late 2017 … Read the full press release